The main condition set by the FTC is that Amgen is prohibited from bundling any of its medicines with two of Horizon’s marketed products – Tepezza (teprotumumab) for thyroid eye disease (TED ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...